1.78 lakh Ayushman Arogya Mandirs operational across India: Govt
"The estimated cost for establishment and maintenance of each AAM is approximately Rs 17.03 lakh, including one-time and recurring annual costs. Funding for AAMs is approved through the National Health Mission's Programme Implementation Plan, submitted by States and Union Territories," Union Minister of State for Health and Family Welfare, Prataprao Jadhav, shard these details in a written reply to the Lok Sabha.
The Ministry also highlighted the 'Free Diagnostics Service Initiative' (FDSI) launched under the National Health Mission in 2015 to provide free pathological and radiological diagnostic services at all levels of public health facilities. The initiative includes 14 tests at Sub Centres and 63 tests at Primary Health Centres.
The AAMs, set up by strengthening Sub Health Centres (SHCs) and Primary Health Centres (PHCs), provide comprehensive primary healthcare, encompassing preventive, promotive, rehabilitative, and curative services. These include management of communicable and non-communicable diseases, reproductive and child healthcare, and other health issues.
Equipped with upgraded infrastructure, essential drugs, diagnostics, trained personnel, and IT systems, the AAMs deliver twelve packages of primary healthcare services closer to people's homes, said Prataprao Jadhav.
Promotive and preventive health form an integral part of care at AAMs, with wellness activities such as yoga, cycling, and meditation being conducted regularly. As of June 30, 2025, over 5.73 crore wellness sessions have been organised.
The Ayushman Bharat Digital Mission (ABDM) aims to establish a digital health ecosystem enabling interoperability of health data across public and private institutions to ensure seamless care. So far, 79.75 crore Ayushman Bharat Health Account (ABHA) IDs have been generated and 65.34 crore Electronic Health Records (EHR) have been linked, said the Minister.
UNI AJ RN
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
12 minutes ago
- Indian Express
Gujarat to prepare SOPs to stop duplicate, fake medicines from entering state
The Gujarat government, in a statement on Tuesday, said it is in the process of formulating Standard Operating Procedures (SOPs) to enhance detection and seizures of duplicate and fake medicines from entering the state. 'Recently, it came to the notice of the state government that fake medicines are entering (Gujarat). They are being sourced from outside the state and sold in some places inside the state. Gujarat's Food and Drug Control Administration (FDCA) has also taken action by conducting on-site inspections. To make this more stringent and strict, the government will prepare an SOP for the inspection of medicines coming from outside the state into Gujarat,' Health Minister Rushikesh Patel was quoted as saying. The SOPs would make registration of imported medicines mandatory, require registration of transporters carrying medicines and cancellation of licenses of chemists or wholesalers who are caught in such dealing with fake medicines. The SOPs will also require people to strictly follow the Drugs and Cosmetics Act. Besides, expensive and 'fast-moving' medicines will be closely monitored. The state government will also start three new testing labs in addition to the existing NABL-certified laboratory in Vadodara. To intensify on-site testing, 10 sets of state-of-the-art hand-held devices (Raman Spectrometer with Advanced Technology) will be purchased. Further, a flying squad will be formed. Patel added that with the implementation of these SOPs, Gujarat will become the first state in the country to adopt 'zero-tolerance' towards duplicate and fake medicines. 'The government will take intensive action to prevent fake/spurious/counterfeit medicines from outside the state in Gujarat. In the last 4 years, raids were conducted to prevent counterfeit medicines/cosmetics in the state and more than Rs 6 crore (worth of) medicines/cosmetics were seized…about 75 persons/firms were found involved and action was taken against them,' a statement read. Speaking about the type of activities unearthed so far, the statement said, 'In most of these cases, persons who do not have a valid license for buying, selling and storing medicines are involved and investigation has also revealed that in most of the cases, counterfeit medicines come from outside the state.'
United News of India
2 hours ago
- United News of India
Aster DM Healthcare to Invest Rs 580 cr in new hospital
Bengaluru, Aug 5 (UNI) Aster DM Healthcare today announced plans to set up its fifth multi-specialty hospital in Bengaluru with an investment of ₹580 crore. The new 500-bedded facility will be located in Yeshwanthpur, taking the total bed capacity of Aster hospitals in the city to 2,580. The new hospital will be built under a Built-to-Suit (BTS) model, consistent with Aster's asset-light expansion strategy. The facility is expected to be operational in the second half of FY 2028–29. The company has entered into a long-term lease agreement with Kemwell Pvt Ltd for 30 years, with provision for renewal. Speaking on the occasion, Dr Azad Moopen, Founder and Chairman of Aster DM Healthcare, said, 'The Yeshwanthpur hospital marks a major milestone in our India growth journey. With this addition, we are poised to become one of the top three healthcare providers in Bengaluru.' The planned facility, with a built-up area of 5 lakh sq ft, will be fully operated and managed by Aster. The group had recently announced a similar model-based hospital on Sarjapur Road. The hospital's location in Yeshwanthpur, a growing urban corridor in northwest Bengaluru, offers connectivity via Tumkur Road, Outer Ring Road, Bellary Road, and the Green Line of Namma Metro, in addition to its proximity to Yeshwanthpur Railway Junction. It will cater to a catchment population of 3–4 million people, including tech parks, industrial areas, and residential hubs. Aster DM Healthcare currently operates 19 hospitals with over 5,000 beds, along with 10 clinics, 203 pharmacies, and 259 labs and patient experience centers across five Indian states. UNI BDN GNK
Time of India
2 hours ago
- Time of India
SME IPO: Medistep Healthcare's Rs 16-cr public issue to open on Aug 8
Pharmaceutical firm Medistep Healthcare is set to raise a little over Rs 16 crore through its initial public offering ( IPO ), which opens for subscription on August 8. The company's maiden public issue will conclude on August 12. The shares are scheduled to be listed on the NSE SME platform on August 18, Medistep Healthcare said in a statement. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program The IPO comprises 37.44 lakh equity shares priced at a fixed Rs 43 per share, aggregating to a total issue size of Rs 16.09 crore. Following the listing, the company is expected to have a market capitalisation of Rs 61.10 crore. The company will utilise the proceeds of the IPO for purchase of plant and machinery for expansion of its existing manufacturing facility, working capital requirements and general corporate purposes. "Proceeds from the IPO will strategically support our expansion efforts and reinforce our footprint in both domestic and international markets," Girdhari Lal Prajapati, Managing Director at Medistep Healthcare, said. Live Events The company is in the business of manufacturing sanitary pads & energy powder, and trading of a diverse range of pharmaceutical products, nutraceutical products, intimate products and surgical products through a distribution network. On the financial front, the company recorded revenue from operations of Rs 49.65 crore in FY25, an increase from Rs 39.07 crore in the preceding fiscal. Its profit after tax (PAT) also rose to Rs 4.14 crore in FY25, compared to Rs 3.33 crore in the previous financial year. Fast Track Finsec is the sole lead manager of the public issue while Cameo Corporate Services is the registrar to the issue.
